London, 6 March 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable), has become the subject of a case study at Harvard Business School for use in courses on corporate governance and boards of directors in both the MBA and executive education programs. The Hikma case study will be used to illustrate the governance transition that a family business undertakes to become a publicly traded company.
Members of the Board of Directors as well as the management team were interviewed for the case study.
Said Darwazah, Executive Chairman of Hikma said “We are extremely proud and very honoured that Harvard Business School has selected Hikma as a case study for its students. It is particularly gratifying to know that students will learn about establishing strong corporate governance from our experience of transitioning from a family business to a public company on the London Stock Exchange.”
The Hikma business case was written by Harvard Professors Lynn Paine and Suraj Srinivasan and research associate Gamze Yucaoglu. Professors Paine and Srinivasan both teach the executive program called “Making Corporate Boards More Effective.” The Hikma case will be used for the first time the in the spring of 2018.
The Hikma case study should be available soon at http://hbsp.harvard.edu/product/cases.